C.S. Mott Children’s Hospital provides comprehensive care for children, adolescents and young adults with all forms of childhood cancer, including offering specialized expertise in rare and resistant brain cancers.
At C.S. Mott Children’s Hospital, your child will have the benefit of an individualized treatment plan developed by a team of specialists in pediatric neurosurgery, pediatric radiation therapy, pediatric oncology and pediatric neuro-oncology, pediatric endocrinology, ophthalmology and pediatric otolaryngology, working hand-in-hand to optimize your child’s care and apply the very latest therapies available.
The pediatric neurosurgery team uses Intraoperative MRI technology to provide a detailed view of brain tumors during surgery, further enhancing the precision of our experienced neurosurgical team.
Our precision oncology program offers the most comprehensive DNA and RNA sequencing capabilities available, guiding each patient’s medical team in the creation of individualized treatment recommendations based on the biologic profile of each patient’s tumor vs. relying on one-size-fits-all therapies using agents designed for adult brain tumors.
The Rehabilitation Psychology/Neuropsychology (RPN) program provides comprehensive psychological care to patients participating in the Milestones Pediatric NeuroRehabilitation Program as part of a multidisciplinary rehabilitation team. Participation in the Pediatric NeuroRehabilitation Program typically follows a hospital admission or other significant medical intervention related to a traumatic or acute health crisis.
The Brain Tumor (CNS) Tumor Precision Medicine Conference is held monthly with the goal of identifying precision-medicine based therapies for pediatric brain tumor patients using molecular info generated from innovative research and clinical tests performed at the University of Michigan. Patient cases are reviewed at each meeting, including pathology results, clinical molecular results, clinical cytogenetics results, Mi-Oncoseq tumor genomic profiling, and information from tumor samples obtained and/or cultured through U-M Brain Tumor Tissue Bank Program.
Each case is discussed with a focus on potential treatment implications, with a multi-disciplinary team including neuro-pathology, pathology/cytogenetics, pharmacology, and research team members. This conference is also tele-conferenced with clinicians/researchers at multiple leading children’s hospitals nationally. Protected health information from cases is removed to respect the privacy of each patient.
C.S. Mott Children’s Hospital offers access to a large pipeline of experimental therapies through our active membership in the Children's Oncology Group Phase I and Phase II-III consortiums. As one of only 20 institutions nationwide able to offer Phase 1 clinical trials to our patients, U-M has the most comprehensive and largest portfolio of clinical trials in the state of Michigan for brain tumors, including many which were developed here at U-M.
Since 2018, The Chad Carr Pediatric Brain Tumor Center has become a destination center for children from around the country (see map) with high-risk brain tumors looking for a promising treatment. Please contact our team of dedicated pediatric brain tumor CRAs if you are interested in a possible referral. [email protected]
- Map of nationwide patient referrals to the Chad Carr Pediatric Brain Tumor Center, a destination center for children with high-risk brain tumors.
Most recently, U-M became the new sequencing home to two key PNOC clinical trials – DMG-ACT (PNOC22) and ONC206 Phase 1 (PNOC23).The University of Michigan was added to the Pacific Neuro-Oncology Consortium (PNOC) in 2019 as the only PNOC institution in the state of Michigan. Read more about PNOC here. This will allow patients at the Chad Carr Pediatric Brain Tumor Center access to multiple early phase trials designed specifically for high-risk pediatric brain tumors. For these PNOC studies, investigators at the University of Michigan will serve in leadership roles on many of the clinical and correlate studies.
Patients enrolled in these trials will be offered sequencing through the MiOncoseq tumor sequencing program. Patients and referring physicians will be provided these CLIA-certified sequencing results. Additionally, sequencing data will be analyzed along with clinical response by U-M Investigators and research collaborators. Sequencing data will be deposited in the PNOC data affiliate Children’s Brain Tumor Network (CBTN) for study by other international sites. By centralizing sequencing at our leading international center for tumor sequencing, we will be ensuring state of the art results for international DIPG/DMG patients, improving the fidelity of the prospective research, and expanding the reach of the U-M Chad Carr Pediatric Brain Tumor Center.
We expect PNOC22 and PNOC23 to open in select U.S. sites in 2021, including the University of Michigan. Generous support from The ChadTough Foundation and Michael Mosier Defeat DIPG Foundation have allowed this sequencing and these trials to open on an expedited schedule.